×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: EU | Britain | Earns | AstraZeneca

Drug Firm AstraZeneca Reports Slide in Earnings

Drug Firm AstraZeneca Reports Slide in Earnings
(REUTERS/Phil Noble)

Friday, 31 July 2015 09:57 AM

LONDON (AP) — Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 percent to $697 million as competition from generic drug companies reduced sales.

Revenue declined 6.7 percent to $6.31 billion as stomach-acid treatment Nexium lost patent exclusivity in the U.S. and cholesterol treatment Crestor faced competition from generic drugs.

CEO Pascal Soriot says the company made "good progress" in the period, with cost reductions supporting investment in science. Soriot also highlighted progress in the company's oncology research, with AstraZeneca receiving regulatory approvals for lung cancer drug Iressa in the U.S. and breast cancer treatment Faslodex in China.

Soirot predicted there would be positive news on the company's drug pipeline in the second half, with regulatory decisions expected for four drugs, including Brilinta, a medication for people who have had heart attacks.

© Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Europe
Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 percent to $697 million as competition from generic drug companies reduced sales.Revenue declined 6.7 percent to $6.31 billion as stomach-acid treatment Nexium lost patent exclusivity in the U.S. and...
EU, Britain, Earns, AstraZeneca
132
2015-57-31
Friday, 31 July 2015 09:57 AM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved